Thursday, December 24, 2009

Sanofi-Aventis - Multaq: not worth it!

Sanofi-Aventis has failed to win early support from the UK's health costs board NICE for its Multaq heart drug on the state-run National Health Service because it is too pricey and no better than existing treatments.

More

No comments: